AgingResearch.NewsJoin free
The Lancet Diabetes & Endocrinology

Drug pair reduced weight in adults with overweight or obesity

Mean weight fell 20.7% with 1.7 mg of each drug and 21.0% with 1.0 mg each, versus 2.0% with placebo over 68 weeks.

Paper by Sean Wharton, Christa Broholm, Deborah Horn, +3 more authorsStephen C Bain
Figure 1 from The Lancet Diabetes & Endocrinology
Open the figure at full size
Figure 1. Wharton et al.

Our read

Interventions
Studied:
Randomized trial in 309 adults with overweight or obesity without diabetes, against pooled placebo (Double-blind, placebo-controlled, multicenter, registered NCT06388187)
What changed:
Mean weight fell 20.7% with 1.7 mg of each drug, versus 2.0% with placebo
The catch:
Novo Nordisk funded the trial
In the record:
The 18th paper on Cagrilintide + semaglutide with results in people; 46 on record in all. Its result on body weight agrees with all 15 other findings on record.

Editor of record: Boris Djordjevic · AgingResearch.News

Paper
Follow @agingbrief

Adults without diabetes who had obesity, or overweight with at least one related complication, took part in a randomized, placebo-controlled phase 3b trial, double-blind within each dose level. The 309 participants averaged 48 years of age; 239 were female and 70 were male.

Participants received weekly injections of cagrilintide and semaglutide, at 1.7 mg each or 1.0 mg each, or placebo for 68 weeks, alongside nutrition and physical activity counseling. In the efficacy analysis, mean weight fell 20.7%, 21.0% and 2.0%, respectively. Adverse events occurred in 102 of 103 participants (99%) at the higher dose, 98 of 103 (95%) at the lower dose and 93 of 102 (91%) with placebo. Most were mild or moderate and related to the digestive system. No deaths were reported.

Why it matters

For weight management as adults age, the authors suggested that different dose levels might support treatment flexibility.

Caveats

The 68-week treatment comparison leaves longer-term weight maintenance unresolved. People with diabetes were excluded, so the findings do not cover that population.

Where the evidence stands

Cagrilintide

Humans: replicated by independent labs. Cells: a single group. Worms or flies and mice: nothing yet.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 8 independent labs in 6 countries
  • 67 trials, 17 with no results posted
  • Funders: Novo Nordisk and 4 more
  • 7 of 14 findings with company ties
  • 67 of 67 trials sponsored by its developers

Semaglutide

Cells, mice and humans: replicated by independent labs. Worms or flies: nothing yet.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 434 independent labs in 62 countries
  • 107 findings against
  • 402 trials, 95 with no results posted
  • Funders: Novo Nordisk and others
  • 391 of 1,592 findings with company ties
  • 217 of 402 trials sponsored by its developers

Comments

Be the first to comment.

More peptides

More on Semaglutide